Related topics

Aimmune Therapeutics: 1Q Earnings Snapshot

May 11, 2020 GMT

BRISBANE, Calif. (AP) _ Aimmune Therapeutics Inc. (AIMT) on Monday reported a loss of $86.4 million in its first quarter.

The Brisbane, California-based company said it had a loss of $1.34 per share. Losses, adjusted for stock option expense and non-recurring costs, came to $1.03 per share.

The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.15 per share.

The food allergy drug developer posted revenue of $575,000 in the period, which did not meet Street forecasts. Six analysts surveyed by Zacks expected $1.8 million.

Aimmune Therapeutics shares have fallen 47% since the beginning of the year. In the final minutes of trading on Monday, shares hit $17.75, a decrease of 13% in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AIMT at https://www.zacks.com/ap/AIMT